European Leukemia Trial Registry
Trial: ALL GMALL Fasturtec in ALL and B-NHL

More Details
Title Fasturtec vs. Allopurinol in hyperuricemia und high risk of tumorlysis-syndrome
Scientific Title Multicentric randomized phase-III study to investigate efficacy and safety of rasburicase (Fasturtec®), compared to treatment of hyperuicemia with allopurinol in patients with acute lymphoblastic leukemia or high-grade non-Hodgkin lymphoma who are at high risk for tumor lysis syndrome (>= 15 years)
Short Title ALL GMALL Fasturtec in ALL and B-NHL
Trialgroup GMALL
Type of Trial multicentric
Disease Acute lymphoblastic leukemia(ALL) All subtypes
Age All ages
Status Closed
Start of Recruitment 01.06.2003
Leader Hoelzer, Prof. Dr. med., Dieter
Contactperson

Study Physician
Gökbuget, Dr. med., Nicola
Tel: +49 (0)69 6301-6366
Fax: +49 (0)69 6301- 7463
Email: goekbuget@em.uni-frankfurt.de

Study Centre
Koy-Redemann, Regina
Tel: +49 (0)69 6301-87146
Fax: +49 (0)69 6301-7463
Email: koy-redemann@em.uni-frankfurt.de

Centre of Trial Universitätsklinikum Frankfurt
Shortprotocol Shortprotocol
created 06.07.2006 Anja Hellenbrecht
changed 10.07.2013 Sina Hehn
© ELIC European Leukemia Information Center | no responsibility is taken for correctness and completeness of this information | www.leukemia-net.org | elic@leukemia-net.org